Strategic partnerships Leverage current collaboration momentum with ALZpath and the AAIC 2026 exposure to position Quanterix Spatial as a preferred partner for Alzheimer’s disease research and diagnostic development, targeting pharma and diagnostics companies seeking robust spatial biology capabilities.

Clinical translational focus Emphasize the shift from research to clinical decision support by showcasing high-speed, single-cell spatial proteomics for disease biology and precision medicine, appealing to academic hospitals, CROs, and biopharma pursuing translational biomarker programs.

Leadership changes Publish targeted outreach around new leadership in finance and diagnostics to highlight stability and strategic方向, offering value propositions tied to cost efficiency, scalable deployment, and accelerated ROI for large and mid-tier biotech customers.

Industry event leverage Capitalize on AAIC 2026 participation by offering pilot programs, case studies, and collaboration opportunities with researchers presenting at the conference, aiming to convert interest into multi-site validation projects.

Mid-market expansion Position Quanterix Spatial as a scalable solution for mid-sized biotech and CROs with revenue in the tens of millions, addressing budget-conscious customers who require reliable, reproducible spatial biology workflows without enterprise-scale pricing.